MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.

@article{Mollaoglu2017MYCDP,
  title={MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.},
  author={Gurkan Mollaoglu and Matthew R. Guthrie and Stefanie Boehm and Johannes Br{\"a}gelmann and Ismail Can and Paul M Ballieu and Annika Marx and Julie George and Christine Heinen and Milind D Chalishazar and Haixia Cheng and Abbie S. Ireland and Kendall E Denning and Anandaroop Mukhopadhyay and Jeffery M Vahrenkamp and Kristofer C. Berrett and Timothy L. Mosbruger and Jun Wang and Jessica L Kohan and Mohamed E. Salama and Benjamin L. Witt and Martin Peifer and Roman K. Thomas and Jason Gertz and Jane E Johnson and Adi F. Gazdar and Robert J Wechsler-Reya and Martin L Sos and Trudy G. Oliver},
  journal={Cancer cell},
  year={2017},
  volume={31 2},
  pages={
          270-285
        }
}
Loss of the tumor suppressors RB1 and TP53 and MYC amplification are frequent oncogenic events in small cell lung cancer (SCLC). We show that Myc expression cooperates with Rb1 and Trp53 loss in the mouse lung to promote aggressive, highly metastatic tumors, that are initially sensitive to chemotherapy followed by relapse, similar to human SCLC. Importantly, MYC drives a neuroendocrine-low "variant" subset of SCLC with high NEUROD1 expression corresponding to transcriptional profiles of human… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 74 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 55 references

Similar Papers

Loading similar papers…